Bicalutamide-induced gynaecomastia: do we have the answer?
Di Lorenzo
Giuseppe
G
Autorino
Riccardo
R
D000813:Anilides / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005500:Follow-Up Studies; D006177:Gynecomastia / Q000139:chemically induced*; D006801:Humans; D015994:Incidence; D008297:Male; D009367:Neoplasm Staging; D009570:Nitriles / Q000009:adverse effects* / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D012307:Risk Factors; D013997:Time Factors; D014105:Tosyl Compounds / Q000009:adverse effects* / Q000627:therapeutic use
D000813:Anilides; D000970:Antineoplastic Agents; D009570:Nitriles; D014105:Tosyl Compounds; C053541:bicalutamide